951884-50-7

Usage

Uses

Used in Organic Synthesis:
Tert-Butyl 2-bromo-4-fluorobenzoate is utilized as a key intermediate in organic synthesis for its ability to participate in various chemical reactions, particularly in the formation of carbon-carbon and carbon-oxygen bonds. Its reactivity makes it a preferred choice for constructing complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, tert-Butyl 2-bromo-4-fluorobenzoate is employed as a building block in the development of new pharmaceutical substances. Its unique structure and reactivity contribute to the creation of novel drug candidates with potential therapeutic applications.
Used in Chemical Reactions:
Tert-Butyl 2-bromo-4-fluorobenzoate is used as a reactant in various chemical reactions to form new compounds with desired properties. Its versatility in participating in different types of reactions, such as esterification, substitution, and condensation, makes it a valuable asset in the field of chemistry.
Used in Material Science:
In material science, tert-Butyl 2-bromo-4-fluorobenzoate can be used as a component in the development of new materials with specific properties. Its chemical structure and reactivity can contribute to the creation of materials with unique characteristics for various applications.

InChI:InChI=1/C11H12BrFO2/c1-11(2,3)15-10(14)8-5-4-7(13)6-9(8)12/h4-6H,1-3H3

Upstream product

• 39982-01-9 tert-Butoxycarbonylpivalat 
• 1006-41-3 2-bromo-4-fluorobenzoic acid 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 1203662-35-4 2-bromo-4-fluoro-3-formylbenzoic acid tert-butyl ester 
• 1203663-13-1 4-[(4-bromo-2-fluorophenyl)amino]-1H-indazole-5-carboxylic acid (2-hydroxyethoxy)amide 
• 1203663-23-3 4-[(2-fluoro-4-iodophenyl)amino]-1H-indazole-5-carboxylic acid cyclopropylmethoxyamide 
• 1203663-21-1 4-[(2-fluoro-4-iodophenyl)amino]-1H-indazole-5-carboxylic acid ethoxyamide 
• 1374328-76-3 4-[(2-fluoro-4-iodophenyl)amino]-1H-indazole-5-carboxylic acid (3-hydroxypropyl)amide 
• 1203663-26-6 [4-[(2-fluoro-4-iodophenyl)amino]-1H-indazol-5-yl]-(3-hydroxyazetidin-1-yl)methanone 
• 1203663-02-8 G-894 
• 1203662-73-0 4-(2-fluoro-4-iodophenylamino)-indazole-1,5-dicarboxylic acid di-tert-butyl ester 
• 1203662-69-4 4-[(4-bromo-2-fluorophenyl)amino]-1H-indazole-1,5-dicarboxylic acid di-tert-butylester 
• 1203663-04-0 4-[(2-fluoro-4-iodophenyl)amino]-1H-indazole-5-carboxylic acid (2-vinyloxyethoxy)amide 
• 1203662-37-6 4-bromo-1H-indazole-5-carboxylic acid tert-butyl ester 
• 1203663-14-2 4-(4-bromo-2-fluorophenylamino)-1H-indazole-5-carboxylic acid (2-vinyloxyethoxy)amide 
• 1203663-12-0 4-(2-fluoro-4-iodophenylamino)-1H-indazole-5-carboxylic acid ((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)amide 
• 1203662-67-2 4-(2-fluoro-4-trimethylsilanylphenylamino)indazole-1,5-dicarboxylic acid di-tert-butyl ester 

Relevant academic research and scientific papers

INDANE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS

The present disclosure provides certain indane compounds that are Hypoxia Inducible Factor 2α (HIF-2α) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2α. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I or Formula II, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, Y1, Y2, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13 are as defined in the specification. The inventive Formula I and Formula II compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactions

Using structure-based design, two novel series of highly potent biaryl amine mitogen-activated protein kinase kinase (MEK) inhibitors have been discovered. These series contain an H-bond acceptor, in a shifted position compared with previously disclosed compounds, and an adjacent H-bond donor, resulting in a bidentate interaction with the Ser212 residue of MEK1. The most potent compound identified, 1 (G-894), is orally active in in vivo pharmacodynamic and tumor xenograft models.

BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS

The invention relates to bicyclic heterocycles of formulae I and II with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.